Clinical Trial

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Study acronym: INDIGO
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)
Protocol Amendment History 35 amendments
This ClinicalTrials.gov record has been amended 35 times since 2022-12-14; most recent amendment 2026-02-02.
Status change: Recruiting → Active, Not Recruiting 2024-12-19
Trial Details
NCT Number NCT05662241
Lead Sponsor Zenas BioPharma (USA), LLC
Collaborators: Bristol-Myers Squibb
Conditions IgG4 Related Disease
Enrollment 194 participants
Start Date 2023-01-09
Primary Completion 2025-11-13 (estimated)
Study Completion 2029-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-02-04